Wounds : a compendium of clinical research and practice · 2025
Use of a novel debriding agent based on collagenase and hyaluronate lyase to enhance angiogenesis, stimulate healing, and reduce pain in chronic cutaneous wounds.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garza-Cerna Jorge Adrián, Mecott-Rivera Gabriel Ángel, Castro-Govea Yanko, Pérez-Trujillo José Juan, de Oca-Luna Roberto Montes, Salas-Treviño Daniel, Kopytina Valeria, Berroa Jorge López
Аннотация
BACKGROUND: Chronic wounds pose a serious health challenge, reducing patient and caregiver quality of life and demanding substantial resources. Debridement is essential for healing, with collagenase being one of the most widely used agents.
OBJECTIVE: To determine the clinical efficacy and safety of a novel bioactive topical formulation combining collagenases G and H, and hyaluronate lyase, for treating chronic ulcers.
MATERIAL AND METHODS: A prospective 2-arm longitudinal comparative interventional study was conducted. Twenty-five patients were allocated into 2 groups and treated for 21 days with conventional dressing. The intervention group (n = 17) additionally received the novel formulation, whereas the control group (n = 8) did not. Epithelialization, angiogenesis, and wound closure were evaluated, as well as patient satisfaction and product safety in terms of pain and adverse effects.
RESULTS: A significantly greater reduction in wound area was observed in the intervention group (baseline median area of 40.0 cm² vs final median area of 16.0 cm²; 60% reduction; P = .0004) compared with controls (baseline median area of 36.0 cm² vs final median area of 24.0 cm²; 33.3% reduction; P = .08). Histological analysis revealed significantly increased angiogenesis in the intervention group (P = .046). The product was rated as highly satisfactory by both physicians and patients in its use and results.
CONCLUSION: The novel formulation demonstrated efficacy in promoting vascularization and reducing the wound area, indicating that it could be a valuable tool for treating chronic ulcers, with significant potential for promoting faster and more effective healing than conventional options.
OBJECTIVE: To determine the clinical efficacy and safety of a novel bioactive topical formulation combining collagenases G and H, and hyaluronate lyase, for treating chronic ulcers.
MATERIAL AND METHODS: A prospective 2-arm longitudinal comparative interventional study was conducted. Twenty-five patients were allocated into 2 groups and treated for 21 days with conventional dressing. The intervention group (n = 17) additionally received the novel formulation, whereas the control group (n = 8) did not. Epithelialization, angiogenesis, and wound closure were evaluated, as well as patient satisfaction and product safety in terms of pain and adverse effects.
RESULTS: A significantly greater reduction in wound area was observed in the intervention group (baseline median area of 40.0 cm² vs final median area of 16.0 cm²; 60% reduction; P = .0004) compared with controls (baseline median area of 36.0 cm² vs final median area of 24.0 cm²; 33.3% reduction; P = .08). Histological analysis revealed significantly increased angiogenesis in the intervention group (P = .046). The product was rated as highly satisfactory by both physicians and patients in its use and results.
CONCLUSION: The novel formulation demonstrated efficacy in promoting vascularization and reducing the wound area, indicating that it could be a valuable tool for treating chronic ulcers, with significant potential for promoting faster and more effective healing than conventional options.